Catalog No.
DHJ82501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-lambda
Clonality
Monoclonal
Target
FzE1, Frizzled-1, hFz1, Fz-1, FZD1
Concentration
1.63 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9UP38
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
OMP-18R5, CAS: 1345009-45-1
Clone ID
Vantictumab
Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review), PMID: 29786110
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review), PMID: 29048660
Molecular genetics and targeted therapy of WNT-related human diseases (Review), PMID: 28731148
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer, PMID: 31338636
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer, PMID: 32803633
Frizzled-7 Is Required for Wnt Signaling in Gastric Tumors with and Without Apc Mutations, PMID: 30622113
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death, PMID: 28691093
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling, PMID: 29151594
Zheng, H., Liu, J., Cheng, Q., Zhang, Q., Zhang, Y., Jiang, L., Huang, Y., Li, W., Zhao, Y., Chen, G., et al. (2024). Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance. Nat Cancer 5, 572-589. PMID: 38291304
For research use only. Not for human or drug use.
